Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Moleculin Biotech, Inc.

Ticker
MBRX
Sector
Industry
Report date
November 14, 2026
Valye AI Score

97

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Moleculin's clinical trial progress, patent achievements, regulatory interactions, and corporate actions.

Recent developments:
  • Moleculin Biotech secured Australian Patent No. 2020303572 for Annamycin formulation technology, strengthening its intellectual property portfolio [N1].
  • The company announced acceptance of Annamycin data for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, enhancing scientific visibility [N2].
  • Moleculin completed dosing in Part A of the pivotal MIRACLE trial, with data readout anticipated in Q1 2027 [N3].
  • The company completed Part A enrollment in the Phase 2/3 MIRACLE trial for relapsed AML, expanding clinical recruitment efforts [N6].
  • Moleculin advanced Annamycin following peer-reviewed cardiac safety data supporting its safety profile [N7].
  • The company effected a 1-for-20 reverse stock split in October 2026 as part of corporate actions [N5].
  • Moleculin posted encouraging Phase 2/3 MIRACLE trial results, although shares declined despite the data [N8].
  • Biotech stocks including MBRX moved higher with MBRX gaining 15%, reflecting market interest [N4].
Overview

Moleculin Biotech, Inc. operates as a clinical-stage biotechnology company specializing in the development of oncology drug candidates. Its lead candidate, Annamycin, is being evaluated in a pivotal Phase 2/3 clinical trial (MIRACLE) targeting relapsed acute myeloid leukemia. The company has completed Part A dosing and enrollment in this trial and is expanding clinical recruitment efforts. Moleculin also develops WP1066, which has shown immune activity and favorable safety in pediatric brain cancer trials. The company holds patents related to Annamycin formulation technology and actively presents clinical data at scientific meetings. Financially, Moleculin reported a net loss and maintains liquidity with cash and current assets exceeding current liabilities as of September 30, 2026. The company is listed on Nasdaq but faces compliance challenges related to minimum bid price requirements.

Executive summary

Moleculin Biotech, Inc. is a clinical-stage biotech company focused on oncology drug development, notably Annamycin and WP1066. The company is advancing Annamycin through a pivotal Phase 2/3 MIRACLE trial for relapsed AML, having completed Part A dosing and enrollment, with data readout anticipated in Q1 2027. Recent peer-reviewed cardiac safety data and patent grants support the drug's development. Financially, as of September 30, 2026, Moleculin held $7.29 million in cash with a current ratio of 1.37, reporting a net loss of $6.49 million for the nine months ended that date. The company faces risks including Nasdaq listing compliance and the need for additional financing to complete clinical development. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for MBRX

Bull case model:

Moleculin's advancement of Annamycin through pivotal clinical trials with encouraging safety and efficacy data, supported by granted patents and regulatory interactions, demonstrates potential for future clinical and commercial milestones. The company’s strategic appointments and expanding clinical programs, including WP1066, add to its development pipeline. Positive peer-reviewed data and acceptance of data presentations at major scientific meetings enhance visibility and credibility within the oncology field.

Bear case model:

Moleculin faces significant risks including the need for substantial additional capital to complete clinical development, potential dilution from warrant exercises and ATM issuances, and challenges maintaining Nasdaq listing compliance due to minimum bid price requirements. As a clinical-stage biotech without approved products, the company’s value is highly dependent on successful clinical trial outcomes and regulatory approvals, which remain uncertain. Failure to maintain listing or secure financing could adversely affect operations and investor confidence.

Moat:

Moleculin Biotech's moat derives from its proprietary oncology drug candidates, particularly Annamycin, supported by granted patents including international formulation patents. The company’s clinical trial progress, including pivotal Phase 2/3 data and peer-reviewed safety findings, contributes to its competitive positioning. Its leadership team has extensive experience in biotech and pharmaceutical development. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical and regulatory outcomes and securing sufficient financing to advance development.

Risks overview
Risks summary
The most significant risks for Moleculin Biotech include maintaining Nasdaq listing compliance, securing sufficient financing to advance clinical development, and the inherent uncertainties of clinical trial outcomes.
Risks details:

• Nasdaq Listing Compliance Risk: The company received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and was granted a limited exception contingent on maintaining compliance through March 15, 2027. Failure to comply could result in immediate delisting, adversely affecting liquidity, financing ability, and investor confidence.
• Financing and Dilution Risk: Moleculin requires substantial additional capital to complete clinical development and commercialization of Annamycin. Future financing may reduce the exercise price of outstanding warrants and dilute existing shareholders. The company has completed public offerings and ATM issuances that have affected warrant exercise prices.
• Clinical Development Risk: As a clinical-stage company, Moleculin’s success depends on positive clinical trial outcomes and regulatory approvals. Delays, unfavorable data, or safety concerns could impede development progress and commercialization potential.

FINAL FORECAST FOR MBRX

Final take one line
Moleculin Biotech is a clinical-stage oncology biotech with well-documented clinical progress, patent protection, and financial disclosures, facing typical development and financing risks.
Final take 12 to 24 month view

Business trends: Advancement of Annamycin through pivotal clinical trials with expanding clinical programs and patent protections.
Execution milestones: Completion of Part A dosing and enrollment in MIRACLE trial, data readout anticipated in Q1 2027, and regulatory presentations.
Key risks: Nasdaq listing compliance challenges, need for additional financing with dilution potential, and inherent clinical development uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

97
LLM visibility overview
LLM Visibility known facts
  • Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing oncology drug candidates, including Annamycin and WP1066.
  • The company is conducting a pivotal Phase 2/3 clinical trial named MIRACLE for Annamycin targeting relapsed acute myeloid leukemia (AML).
  • Part A dosing of the MIRACLE trial has been completed, with data readout anticipated in Q1 2027.
  • The company has completed Part A enrollment in the MIRACLE trial and is expanding clinical recruitment efforts, including securing RAMPA approval in Georgia for Phase 2B/3.
  • Moleculin has reported encouraging Phase 2/3 MIRACLE trial results and positive preclinical data for Annamycin in pancreatic cancer.
  • Peer-reviewed cardiac safety data for Annamycin has been published, supporting advancement of the drug candidate.
  • Moleculin secured an Australian patent for Annamycin formulation technology.
  • Annamycin data has been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
  • The company completed a 1-for-20 reverse stock split in October 2026.
  • Moleculin's WP1066 showed immune activity and favorable safety in a pediatric brain cancer Phase 1 trial.
  • The company has appointed Adriano Treve as a strategic advisor to enhance partnerships and advance clinical trials.
  • Moleculin's common stock is listed on Nasdaq but has faced challenges meeting minimum bid price requirements, receiving a Nasdaq exception with compliance conditions through March 15, 2027.
  • As of September 30, 2026, the company had $7.29 million in cash and cash equivalents, current assets of $8.41 million, current liabilities of $6.14 million, a current ratio of 1.37, and a cash ratio of 1.19.
  • The company reported a net loss of $6.49 million for the nine months ended September 30, 2026, with basic EPS of -$9.59 per share.
  • Moleculin requires additional financing to complete clinical development and commercialization of Annamycin, with potential dilution effects from warrant exercises and ATM issuances.
  • The company’s executive leadership includes Walter V. Klemp as Chairman, President, and CEO, Jonathan P. Foster as Executive VP and CFO, and Donald Picker, PhD, as Chief Scientific Officer.
  • Risk factors include potential Nasdaq delisting if compliance with listing rules is not maintained, and the need for substantial additional capital to fund clinical development.
  • The company’s business model centers on advancing oncology drug candidates through clinical trials, regulatory approvals, and eventual commercialization.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-14 | 10-K/A
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Moleculin Biotech, Inc. Secures Australian Patent No. 2020303572 for Annamycin Formulation Technology | https://www.nasdaq.com/articles/moleculin-biotech-inc-secures-australian-patent-no-2020303572-annamycin-formulation
  • N2 | 2026-11-05 | www.nasdaq.com | Moleculin Biotech, Inc. Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting | https://www.nasdaq.com/articles/moleculin-biotech-inc-announces-acceptance-annamycin-data-presentation-2026-american
  • N3 | 2026-10-30 | www.nasdaq.com | Moleculin Completes Dosing In Part A Of Pivotal MIRACLE Trial; Data Readout Expected In Q1 2027 | https://www.nasdaq.com/articles/moleculin-completes-dosing-part-pivotal-miracle-trial-data-readout-expected-q1-2027
  • N4 | 2026-10-20 | www.nasdaq.com | Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40% | https://www.nasdaq.com/articles/biotech-stocks-move-higher-mbrx-gains-15-femy-rises-7-rvmd-advances-7-mygn-surges-over-40
  • N5 | 2026-10-16 | www.nasdaq.com | Moleculin Biotech To Effect 1-for-20 Reverse Stock Split | https://www.nasdaq.com/articles/moleculin-biotech-effect-1-20-reverse-stock-split
  • N6 | 2026-09-29 | www.nasdaq.com | Moleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AML | https://www.nasdaq.com/articles/moleculin-completes-part-enrollment-phase-2-3-miracle-trial-relapsed-aml
  • N7 | 2026-09-28 | www.nasdaq.com | Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data | https://www.nasdaq.com/articles/moleculin-advances-annamycin-following-peer-reviewed-cardiac-safety-data
  • N8 | 2026-06-30 | www.nasdaq.com | Moleculin Posts Encouraging Phase 2/3 MIRACLE Trial Results; Shares Down Despite Data | https://www.nasdaq.com/articles/moleculin-posts-encouraging-phase-2-3-miracle-trial-results-shares-down-despite-data
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine